EMA defers decision on MS drug Laquinimod

[MSUK]

The Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) decided on Friday to defer a decision on Laquinimod, an oral treatment for relapsing-remitting multiple sclerosis (RRMS). Laquinimod is being developed jointly by Teva Pharmaceutical Industries Ltd, and Swedish company Active Biotech. According to Active Biotech, the EMA will issue an opinion at its January, 2014 meeting...... Read More - http://www.ms-uk.org/laquinimod